Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer < em > EGFR < /em > Exon 20 insertion mutations after platinum-based chemotherapy

CONCLUSION: In the absence of clinical evidence from randomized clinical trials, this study reflects the benefit of amivantamab after platinum-based chemotherapy for advanced non-small cell lung cancer patients harboring EGFR Exon 20ins, compared to current real-world therapies.PMID:37938161 | DOI:10.1080/0284186X.2023.2254479

Source: Acta Oncologica - November 8, 2023 Category: Cancer & Oncology Authors: Tae Min Kim Nicolas Girard Grace Kah Mun Low Jianmin Zhuo Dae Young Yu Yishen Yang Maiko Murota Cindy Thiow Koon Lim Nora J Kleinman Byoung Chul Cho Source Type: research